ID   SKOV3.ip1
AC   CVCL_0C84
SY   SKOV3-ip1; Skov3-ip1; SKOV3ip1; SKOV3IP1; SKOV3IP
DR   BTO; BTO:0006557
DR   cancercelllines; CVCL_0C84
DR   PRIDE; PXD003668
DR   Wikidata; Q54954770
RX   PubMed=8094034;
RX   PubMed=23552738;
RX   PubMed=27561551;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0532 ! SK-OV-3
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 18
//
RX   PubMed=8094034;
RA   Yu D.-H., Wolf J.K., Scanlon M., Price J.E., Hung M.-C.;
RT   "Enhanced c-erbB-2/neu expression in human ovarian cancer cells
RT   correlates with more severe malignancy that can be suppressed by
RT   E1A.";
RL   Cancer Res. 53:891-898(1993).
//
RX   PubMed=23552738; DOI=10.1038/oncsis.2012.22;
RA   Lee J., Bartholomeusz C., Krishnamurthy S., Liu P., Saso H.,
RA   LaFortune T.A., Hortobagyi G.N., Ueno N.T.;
RT   "PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits
RT   ovarian cancer cell tumorigenicity and progression through blocking
RT   beta-catenin.";
RL   Oncogenesis 1:e22.1-e22.11(2012).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//